Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (206)	12/17/1997 12:44:00 PM
From: Howard Frederick	Read Replies (1) \| Respond to of 1494

// There has been no announcement of delisting. The stock is getting hammered for no apparent reason. IMO, it is a combination of tax loss selling and a fear of delisting. However, lost in the shuffle is the fact that NTII will have results from the Phase II neuropathic pain trial in January. If these results are positive, and I'm very optimistic // My take is that the stock is getting hammered primarily because of fears it may no longer be a going concern. The results of the above metioned Phase II trial cannot be overstated. If the results are good enough to cause optimism about Memantine and a favorable partnership, you can get multiples on your money at these levels. If the results are inconclusive or poor, you may only get a fraction of these levels back. NTII would almost certainly no longer be in business, the only question being what it would be sold for. Delisting would be the least of your problems. I still own some stock in NTII, and sincerely hope the trial shows good results. Also considering picking up more at these levels. Regardless, this stock is a huge gamble.

To: Dr. John M. de Castro who wrote (206)	12/23/1997 9:25:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

NTII is being demoted to the NASDAQ SmallCap Market: Dow Jones Newswires -- December 23, 1997 Neurobiological Tech To Be Delisted From Nasdaq Natl Mkt RICHMOND, Calif. (Dow Jones)--Neurobiological Technologies Inc. (NTII) will be moved from a listing on to the Nasdaq SmallCap Market effective Dec. 26, from the Nasdaq National Market. In a press release Tuesday, Neurobiological said its common stock will be listed on the SmallCap Market under an exception to the initial net tangible assets requirement and a waiver to the initial per share bid price requirement. Neurobiological failed to meet the tangible assets requirement as of June 30, but was granted a temporary exception from the standard, subject to meeting certain conditions. The exception will expire on Jan. 15, 1998. The company will be required to meet the $1 a share bid price requirement for continued listing by Jan. 15, 1998. If the company fails to meet SmallCap requirements, it may continue to be listed on the Bulletin Board. Effective Dec. 26, and for the duration of the exception, the company's Nasdaq symbol will be "NTIIC." Neurobiological's stock closed unchanged at 7/8. Neurobiological Technologies is a drug development company.